Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dexfenfluramine

Drug Profile

Dexfenfluramine

Alternative Names: Adifax; D-fenfluramine; Dextrofenfluramine; Dipondal; IP 001 - Servier; Isomeride; Obedial; Redux; S 5614

Latest Information Update: 25 Sep 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Servier
  • Class Anorectics; Small molecules
  • Mechanism of Action Serotonin release stimulants; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Market Withdrawal Obesity

Most Recent Events

  • 27 Apr 2000 Fenfluramine/dexfenfluramine has been withdrawn in Europe
  • 28 Sep 1998 Results of 3 studies looking at the evidence linking anorectics with valvular heart disease have been added to the Adverse Events section ,,,
  • 05 Jun 1998 Launched for Obesity in Europe (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top